{"id":"NCT01968213","sponsor":"pharmaand GmbH","briefTitle":"Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)","officialTitle":"A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-07","primaryCompletion":"2017-04-01","completion":"2022-07-07","firstPosted":"2013-10-23","resultsPosted":"2018-08-03","lastUpdate":"2023-06-09"},"enrollment":564,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer"],"interventions":[{"type":"DRUG","name":"Rucaparib","otherNames":["CO-338","PF 01367338","AG 14699"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rucaparib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus placebo. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.","primaryOutcome":{"measure":"Disease Progression According to RECIST Version 1.1, as Assessed by the Investigator, or Death From Any Cause (Investigator Progression Free Survival as Per invPFS)","timeFrame":"Every 12 calendar weeks (within 7 days prior is permitted) after start of treatment until treatment discontinuation due to disease progression. Total follow-up was up to approximately 3 years.","effectByArm":[{"arm":"Rucaparib 600 mg Tablets","deltaMin":10.8,"sd":null},{"arm":"Placebo Tablets","deltaMin":5.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":96,"countries":["United States","Australia","Belgium","Canada","France","Germany","Israel","Italy","New Zealand","Spain","United Kingdom"]},"refs":{"pmids":["37262961","35397664","35170751","32861537","32359490","28916367"],"seeAlso":["http://www.arielstudy.com"]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":372},"commonTop":["Nausea","Fatigue","Constipation","Diarrhoea","Abdominal pain"]}}